PDL Pulls The Plug On Nuvion Program After Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Interim analysis from a Phase III study of the investigational ulcerative colitis therapy shows insufficient efficacy and an inferior safety profile, company reports.
You may also be interested in...
PDL Can’t Find Buyer, Plans More Cutbacks
Fourth-quarter numbers disappoint, but savings could brighten picture.
PDL Can’t Find Buyer, Plans More Cutbacks
Fourth-quarter numbers disappoint, but savings could brighten picture.
PDL BioPharma Plans To Divest Assets, Emerge As Pure Play Biotech
Sale of PDL’s lucrative royalty stream or even the company itself is not off the table as reorganization unfolds.